In focus · trending topic

first and only

1 stories · following the connections

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

By Nasdaq OMXAug 24, 2017, 8:16 PM UTC